Intervet Has Developed Bluetongue Vaccine

“We can now provide a safe and efficacious vaccine helping to fight this devastating disease”, says Paul van Aarle, Director Institutional Sales of Intervet. “We are currently optimizing the production process and we expect to have more insight in the overall production capacities by March.”

The UK Department for Environment, Food and Rural Affairs (Defra), already placed an order with Intervet to supply 22.5 million doses of Bluetongue vaccine. Intervet’s Bluetongue vaccine recently gained a temporary license in France. Based on this license, other member states of the European Union can allow usage of the vaccine to control the disease.

As the global leader in the development and supply of vaccines to support animal health and welfare, Intervet has been actively working on a vaccine against this virus since its emergence in Northern Europe in 2006 to meet the urgent need as quickly as possible.

The vaccine has been developed for sheep and for cattle. While sheep need to be vaccinated only once, cattle will need two vaccinations. The Bluetongue control strategy and vaccine purchase and supply are defined by the national authorities.

Sign up for our
regular news updates

Latest Cattle Industry News

•   BSE NEWS: Variant More Virulent than Classical Form
•   BLUETONGUE: Dutch Opt for Voluntary Vaccination
•   Boosting the Bottom Beef Line
•   At One With Nature: Fonterra Commits to Environment
•   Keeping Afloat in the Turbulent UK Beef Market
•   Union Stops Chasing the Badger Cull
•   Dairy Demand Drops in Heat of Economy
•   Bid to Cut Emissions as Consumption Increases
•   Hong Kong Concerned with Beef Tampering
•   New Animal Health Lab Likely to be in Kansas
•   Voting Starts for Alpharma Video Contest
•   Violence in Pakistan Disrupts Milk Trade
•   Industry Veteran Joins Dairy Farmers Of America
•   CME: Live Cattle Futures Take Downward Path
•   The Changing Face of Bovine Ephemeral Fever